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We	 report	 a	 case	 of	 probable	 Zaire	 Ebola	 virus–related	
ophthalmologic complications in a physician from the 
United	States	who	contracted	Ebola	virus	disease	in	Libe-
ria.	 Uveitis,	 immune	 activation,	 and	 nonspecific	 increase	
in antibody titers developed during convalescence. This 
case highlights immune phenomena that could compli-
cate	 management	 of	 Ebola	 virus	 disease–related	 uveitis	 
during convalescence.
The Case-Patient
Fever developed in a physician providing health care in 
Liberia on August 29th, 2014 (day 0). The physician was 
positive for EBOV by reverse transcription PCR (RT-PCR) 
of plasma and was evacuated to the United States. Details 
of his acute phase clinical course and management were 
recently described (1).
The patient was given investigational drug TKM-100-
802 siRNA LNP (Tekmira Pharmaceuticals, Burnaby, Brit-
ish Columbia, Canada). He also received convalescent-phase 
plasma from a survivor of EVD on day 9. During hospital-
ization, bilateral conjunctivitis (1) developed, but it resolved. 
He did not undergo formal ophthalmologic examination or 
report ocular symptoms and was discharged on day 26.
The patient came to the UMass Memorial Medical Cen-
ter (Worcester, MA, USA) 37 days after onset of EVD with 
a 2-day history of nonproductive cough, low-grade fever, and 
generalized weakness. He was given azithromycin for sus-
pected pneumonia. The patient reported irritation and redness 
of the left eye and was given topical polymyxin B sulfate/
trimethoprim for presumed conjunctivitis. Blood cultures and 
nasal wash and swab specimens were negative for respiratory 
pathogens (online Technical Appendix, http://wwnc.cdc.gov/
EID/article/22/2/15-1416-Techapp1.pdf). RT-PCR result for 
a plasma specimen was negative for EBOV RNA.
The patient came to the UMass Memorial Eye Center 
on October 7, 2014 (day 40), with a 1-day history of painful 
vision loss, redness, and photophobia of the left eye. Re-
sults of review of other systems were negative. His medical 
history included treated latent tuberculosis and presumed 
acute Lyme disease treated in June 2014 with doxycycline.
He reported no history of ocular problems. Best cor-
rected visual acuity was 20/25 in the right eye and 20/70 
in the left eye. Intraocular pressures were 20 mm Hg in the 
right eye and 8 mm Hg in the left eye. Results of examina-
tion of the right eye were not remarkable. Slit lamp exami-
nation of the left eye showed diffuse blood vessel injection, 
mild corneal edema with fine inferior keratic precipitates, 
fibrin reaction, and leukocytes in the anterior chamber 
without hypopyon (Figure 1). The anterior vitreous humor 
was clear. The left fundus viewed by indirect ophthalmos-
copy was hazy because of anterior segment findings but 
showed a grossly normal posterior segment. The patient 
was initially given topical 1% topical prednisolone acetate 
(every hour while awake) and 1% homatropine (2×/d). 
These drugs were gradually tapered over several weeks as 
he showed clinical improvement.
EBOV transmission was a concern because of reports of 
prolonged viral shedding on the ocular surface (2–4). After 
consent was obtained, the patient remained in home isola-
tion pending results of conjunctival swab specimen testing. 
On day 42, one dry conjunctival swab specimen and 1 con-
junctival swab specimen (in viral transport medium) from 
the inferior fornix of each eye were collected (online Tech-
nical Appendix). Specimens were shipped to the Centers for 
Disease and Prevention (CDC; Atlanta, GA, USA), and all 
showed negative results by RT-PCR for EBOV RNA.
On day 50, the patient had worsened best corrected 
visual acuity in the left eye (20/200) and increased floaters 
despite improved anterior chamber findings. Fundus exami-
nation demonstrated vitreous haze (standardization of uveitis 
nomenclature [5] classification grade 2–3 and classification 
grade 6 of Davis et al. [6]). No choroidal or retinal lesions 
were noted. Spectral domain ocular coherence tomography 
(Heidelberg Engineering, Carlsbad, CA, USA) showed dif-
fuse vitreous opacity and vitreous adhesions that appeared 
as small particles in a line of vitreous strands (Figure 2). In 
addition, In addition, spectral domain−optical coherence 
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tomography imaging showed cystoid macular edema and 
vitreous adhesions tethered to the optic disc.
Diagnostic studies for etiologies of uveitis were per-
formed on day 54. Results were positive for human leuko-
cyte antigen (HLA)–B27 haplotype. We found increased 
levels of IgM and IgG against cytomegalovirus, Epstein-
Barr virus, and varicella zoster virus. Lyme disease 
screening with confirmatory Western blot showed IgM 
against Borrelia burgdorferi (IgG Western blot result was 
negative). The perinuclear–antineutrophil cytoplasmic an-
tibody titer was 1:80, and the erythrocyte sedimentation 
rate (48 mm/h) was increased. Complete laboratory data 
are shown in the online Technical Appendix. The patient 
showed persistence of EBOV RNA virus in semen during 
convalescence (CDC, unpub. data).
The patient was given prednisone (60 mg/d), and pos-
terior segment inflammation had improved at follow-up 4 
days later. Intraocular fluid sampling was considered for 
identifying EBOV RNA in aqueous or vitreous humors 
pending progress of the clinical course of the patient, but 
because his ocular inflammation responded well to medical 
therapy, this sampling was deferred.
Tapering of prednisone was initiated 1 week after 
treatment. Seven weeks (day 89) after initial presentation, 
left eye visual acuity increased to 20/25. As of March 2015, 
the patient was asymptomatic and his visual acuity was 
20/20. The posterior segment was clear, and repeat spectral 
domain ocular coherence tomography confirmed normal 
macular structure (Figure 2).
We implemented universal precautions during exami-
nations and designated 1 examination room and a set of 
equipment for office visits. Personal protective equipment 
used is detailed in the o nline Technical Appendix. Signs or 
symptoms of illness did not develop in any staff who cared 
for the patient.
Conclusions
EVD evolved in December 2013 from a regional outbreak 
in West Africa to a major global health concern (7). As 
the number of survivors of Ebola increases, evaluation of 
Figure 1.	Slit	lamp	examination	of	the	left	eye	of	a	physician	from	
the	United	States	who	contracted	Ebola	virus	disease	in	Liberia	and	
had	eye	inflammation	develop	during	convalescence.	Image	shows	
diffuse	conjunctival	injection,	mild	corneal	edema	with	fine	inferior	
keratic	precipitates,	fibrin	reaction,	and	leukocytes	in	the	anterior	
chamber	without	hypopyon.	Used	with	permission	of	the	patient.
Figure 2. Color fundus and 
optical coherence tomography 
(OCT) images during active 
uveitis and after resolution for 
a	physician	from	the	United	
States who contracted Ebola 
virus disease in Liberia and 
had	eye	inflammation	develop	
during convalescence. A) Color 
fundus image of the left eye 
showing a hazy view to the 
posterior pole during active 
uveitis (standardization of uveitis 
nomenclature	classification	grade	
2–3).	B)	Color	fundus	image	
of the left eye showing a clear 
view to the posterior pole after 
resolution of uveitis. C) OCT of 
macula showing vitreous debris 
and small particles in a line of 
vitreous strands, consistent with 
inflammatory	debris.	D)	OCT	of	
macula showing resolution of 
vitreous	and	inflammatory	debris.	
Scale	bars	indicate	200	µm.
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ocular disease, particularly uveitis, will be a major com-
ponent of patient management. Evaluation of non-EVD 
causes of uveitis in this patient showed notable results. 
First, he was positive for HLA-B27. This major histocom-
patibility class I allele has a well-recognized association 
with anterior uveitis (8). It is unclear whether this HLA 
status contributed to development of uveitis in the context 
of recent EVD. Second, there was evidence of global im-
mune activation (increased erythrocyte sedimentation rate) 
and dysregulation of antibody production given the broad 
spectrum of positive serologic results, all of which fully 
returned to reference values on repeat testing after cortico-
steroid treatment (online Technical Appendix).
Lymphocyte responses have been described in humans 
with EVD, and sustained responses have been noted up to 
60 days after symptom onset (9). Prolonged presence of 
activated virus-specific lymphocytes might be caused by 
retained viral antigen despite undetected EBOV viral load. 
Antibody-producing plasmablasts levels increased during 
acute EVD, and measures of EBOV-specific responses 
suggested polyclonal expansion, including cells with oth-
er specificities (9). The pronounced increase in levels of 
serologic markers observed for this patient suggests that 
dysregulation of antibody production might contribute to 
immunopathogenesis and provides supporting evidence of 
a robust inflammatory response during EVD. Health care 
providers should be aware that the usual laboratory workup 
for uveitis might be confounding in the setting of recent 
EBOV infection.
We considered the possibility of an immune reaction 
secondary to recent treatment with TKM-100-802 siRNA 
LNP and convalescent-phase plasma from survivors of 
EVD. However, little data are available regarding these 
treatments and immune potentiation or uveitis. Larger trials 
would be necessary to evaluate these potential associations.
Similar to results of Varkey et al. (10), we did not de-
tect EBOV RNA in conjunctival samples. However, the 
findings of viable EBOV persisting in aqueous humor dur-
ing convalescence (10) and EBOV in semen in convales-
cent-phase samples (2,11) provides evidence that EBOV is 
harbored in immune-privileged organs. EBOV RNA was 
detected in semen specimens from our patient, and testing 
has yielded positive results (CDC, unpub. data).  It remains 
unclear whether EVD-associated uveitis is caused by cy-
topathic effect of the virus or immune response, but early 
use of systemic corticosteroids appears to be beneficial, and 
sampling of intraocular fluid might not be necessary in pa-
tients who clinically improve with medical therapy.
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Technical Appendix 
Conjunctival Swab Specimen Collection during Ebola Virus Disease 
1) Don (put on) personal protective equipment (PPE) in compliance with Centers 
for Disease Control and Prevention (CDC) recommendations during hospitalization for 
Ebola virus disease (1). When collecting specimens from patients who have recovered 
from Ebola virus disease, standard, contact, and droplet precautions should be followed. 
2) Clean periorbital skin with sterile saline or sterile water and apply topical anesthetic as 
needed. 3) Pass a dry swab over the right lower conjunctival sac 5–6 times to obtain 
epithelial cells. 4) Immediately place swab into tube of viral transport medium. 5) Repeat 
the above process for the left eye. 6) Repeat for the right eye and left eye for a total of 2 
swab specimens in viral transport medium for each eye. 7) Obtain 2 sets of swab 
specimens for each eye in a similar fashion for transport in dry containers (dry swab 
samples). 8) Doff (take off) PPE in compliance with CDC recommendations (1). 9) 
Contact the state public health department and refer to CDC guidance on collection, 
labeling, laboratory handling, transport, and submission of specimens potentially 
contaminated with Ebola virus (2). 
Personal Protective Equipment 
Standard, contact, and droplet precautions are recommended when evaluating 
patients who have survived Ebola virus disease and have ocular complications. Health 
care personnel must be trained and competent in correct use of recommended PPE, and a 
trained observer should monitor and confirm adherence to the proper use of PPE by 
others. 
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Technical Appendix Table 1. Laboratory results for possible etiology of uveitis in patient with Ebola virus disease, 
October 2014* 
Test  Result Comment Reference value or range 
ANCA screening with MPO/PR3, reflex to ANCA titer P-ANCA positive High NA 
Myeloperoxidase antibody titer <1.0 Negative <1.0: no antibody detected; >1.0: 
antibody detected 
Proteinase 3 antibody titer <1.0 Negative <1.0: no antibody detected; >1.0: 
antibody detected 
Complement C3c, mg/dL 85 Low 90–180 
Complement C4c, mg/dL 15 Low 16–47 
Complement C50, total, U/mL 41 Negative 31–60 
CRP, mg/L <1.0 Negative <10 
ESR, Westergren, mm/h 48 High 0–20 
Rheumatoid factor, IU/mL 12 Negative <14 
Cyclic citrullinated peptide IgG titer, U <1:16 Negative <20: negative; 20–39: weak positive; 
40–59: moderate positive; >59: strong 
positive 
Cytomegalovirus IgG titer 3.98, positive High <0.90: negative; 0.91–1.09: equivocal; 
>1.10: positive 
Cytomegalovirus IgM titer >4.0, positive High <0.8: no antibody detected; 0.9–1.0: 
equivocal; >1.1: antibody detected 
EBV IgG titer >5.00, positive High <0.90: negative; 0.91–1.09: equivocal; 
>1.10: positive 
EBV IgM titer 4.28, positive High <0.90: negative; 0.91–1.09: equivocal; 
>1.10: positive 
EBV nuclear antigen antibody titer >5.00, positive High <0.90: negative; 0.91–1.09: equivocal; 
>1.10: positive 
HSV 1 IgG/IgM titer <0.90 Negative <0.90: negative; 0.91–1.09: equivocal; 
>1.10: positive 
HSV 2 IgG/IgM titer <0.90 Negative <0.90: negative; 0.91–1.09: equivocal; 
>1.10: positive 
HIV-1 DNA, qualitative TMA NR NA NA 
Lyme disease antibody screening 2.64 Positive <0.90: negative; 0.91–1.09: equivocal; 
>1.10: positive 
Lyme disease IgG Negative NA NA 
23-kD IgG band Reactive NA NA 
41-kD IgG band Reactive NA NA 
Lyme disease IgM Positive NA NA 
23-kD IgM band Reactive NA NA 
39-kD IgM band Reactive NA NA 
41-kD IgM band Reactive NA NA 
Toxoplasma IgG titer <0.90 Negative <0.90: negative; 0.91–1.09: equivocal; 
>1.10: positive 
Toxoplasma IgM titer Negative NA NA 
Uric acid, mg/dL 3.7 Negative 2.5–8.0 
VZV IgG titer 3.18, positive High <0.90: negative; 0.91–1.09: equivocal; 
>1.10: positive 
VZV IgM titer 2.40, positive High <0.90: negative; 0.91–1.09: equivocal; 
>1.10: positive 
Treponema pallidum, total FTA-ABS NR NA NA 
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Test  Result Comment Reference value or range 
Lysozyme, g/mL 10.4 Negative 7.0–15.0 
ACE, U/L 80 High 9–67 
ANA screening by IFA Negative NA NA 
Malaria screening Negative NA NA 
CBC    
 Leukocytes, × 103/mm3 6.3 NA 4.3–10.3 
 Erythrocytes, × 106/mm3 3.62 Low 4.40–6.00 
 Hemoglobin, g/dL 10.8 Low 4.40–6.00 
 Hematocrit, % 32.0 Low 42.0–52.0 
 MCV, fL 88.4 NA 82.0–101.0 
 MCH, pg 29.8 NA 27.0–34.0 
 MCHC, g/dL 33.7 NA 31.5–36.0 
 RDW, % 18.0 High 12.1–14.6 
 Platelet count, × 103/mm3 312 NA 140–440 
 Mean platelet volume, fL 7.0 Low 7.6–11.6 
 Neutrophils, % 56.6 NA 43.0–72.0 
 Lymphocytes, % 39.8 NA 18.0–43.0 
 Monocytes, % 3.4 Low 4.0–12.0 
 Eosinophils, % 0.0 NA NA 
 Basophils, % 0.2 NA NA 
 Absolute no. neutrophils, × 103/mm3 3.57 NA NA 
 Absolute no. lymphocytes, × 103/mm3  2.5 NA NA 
 Absolute no. monocytes, × 103/mm3  0.2 NA NA 
 Absolute no. eosinophils, × 103/mm3   0.0 NA NA 
 Absolute no. basophils, × 103/mm3  0.0 NA NA 
 Erythrocyte morphology: anisocytosis 1+ NA NA 
 Erythrocyte morphology: microcytosis 1+ NA NA 
 Erythrocyte morphology: polychromasia 1+ NA NA 
 Platelet morphology: large Present NA NA 
 Platelet estimate ADQ NA NA 
PCR (respiratory pathogens)    
 Adenovirus ND NA NA 
 Bordetella pertussis ND NA NA 
 Chlamydophila pneumoniae ND NA NA 
 Coronavirus 229E ND NA NA 
 Coronavirus HKU1 ND NA NA 
 Coronavirus NL63 ND NA NA 
 Coronavirus OC43 ND NA NA 
 Human metapneumovirus ND NA NA 
 Human rhinovirus/enterovirus ND NA NA 
 Influenza 2009 virus, H1 subtype ND NA NA 
 Influenza A virus, H1 subtype ND NA NA 
 Influenza A virus, H3 subtype ND NA NA 
 Influenza B virus ND NA NA 
 Mycoplasma pneumonia ND NA NA 
 Parainfluenza virus 1 ND NA NA 
 Parainfluenza virus 2 ND NA NA 
 Parainfluenza virus 3 ND NA NA 
 Parainfluenza virus 4 ND NA NA 
 Respiratory syncytial virus ND NA NA 
Protein electrophoresis    
 Protein, total, g/dL 7.3 NA 6.1–8.1 
 Interpretation Normal pattern NA NA 
 -globulins, g/dL 0.8 NA 0.8–1.4 
 2-globulins, g/dL 0.7 NA 0.5–1.0 
 1-globulins, g/dL 0.3 NA 0.1–0.3 
 Albumin g/dL, g/dL 4.1 NA 3.5–4.7 
 -globulins, g/dL 1.5 NA 0.6–1.6 
BMP    
 Sodium, mmol/L 139 NA 135–145 
 Potassium, mmol/L 4.2 NA 3.5–5.3 
 Chloride, mmol/L 101 NA 97–110 
 Carbon dioxide, mmol/L 25 NA 24–32 
 Anion gap, mg/dL 13 NA 5–15 
 Glucose, mg/dL 97 NA 70–99 
 Blood urea nitrogen, mg/dL 12 NA 7–23 
 Urine creatinine, mg/dL 1.10 NA 0.60–1.30 
 Glomerular filtration rate, mL/min >60 NA >60 
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Test  Result Comment Reference value or range 
 Calcium (ionized, whole blood) mg/dL 4.6 NA 4.6–5.3 
*ANCA, antineutrophil cytoplasmic antibody; MPO/PR3, myeloperoxidase/proteinase 3; P-ANCA, perinuclear ANCA; NA, not applicable; CRP, C-reactive 
protein: ESR, erythrocyte sedimentation rate; EBV, Epstein-Barr virus; HSV, herpes simplex virus; TMA, transcription-mediated amplification; NR, not 
reactive; VZV, varicella zoster virus; FTA-ABS, fluorescent treponemal antibody absorption test; ACE, angiotensin-converting enzyme; ANA, antinuclear 
antibody; IFA, immunofluorescence assay; CBC, complete blood count; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin 
concentration; RDW, red blood cell distribution width; ADQ, adequate; ND, not detected; BMP, basic metabolic panel. 
 
 
 
 
 
Technical Appendix Table 2. Repeat laboratory results for possible etiology of uveitis in patient with Ebola virus disease, 
April 2015* 
Test Result Comment Reference value or range 
ANCA screening with MPO/PR3, reflex to 
ANCA titer 
Negative Negative NA 
Myeloperoxidase antibody titer <1.0 Negative <1.0: no antibody detected; >1.0: antibody detected 
PR3 antibody titer <1.0 Negative 1.0: no antibody detected; >1.0: antibody detected 
CRP (January 2015), mg/L <1.0 Negative <10 
ESR, Westergren, mm/h 11 Negative 0–20 
Cytomegalovirus IgG titer 2.78, positive High <0.90: negative; 0.91–1.09: equivocal; >1.10: positive 
Cytomegalovirus IgM titer 0.7 Negative <0.8: no antibody detected; 0.9–1.0 equivocal; >1.1: 
antibody detected 
EBV IgG titer >5.00, positive High <0.90: negative; 0.91–1.09: equivocal; >1.10: positive 
EBV IgM titer <0.90 Negative <0.90: negative; 0.91–1.09: equivocal; >1.10: positive 
EBV nuclear antigen IgG titer >5.00, positive High <0.90: negative; 0.91–1.09: equivocal; >1.10: positive 
Lyme disease antibody titer <0.90 Negative <0.90: negative; 0.91–1.09: equivocal; >1.10: positive 
VZV IgG titer 2.62, positive High <0.90: negative; 0.91–1.09: equivocal; >1.10: positive 
VZV IgM titer <0.90 Negative <0.90: negative; 0.91–1.09: equivocal; >1.10: positive 
*ANCA, antineutrophil cytoplasmic antibody; NA, not applicable; MPO/PR3, myeloperoxidase/proteinase 3; CRP, C-reactive protein: ESR, erythrocyte 
sedimentation rate; EBV, Epstein-Barr virus; VZV, varicella zoster virus. 
 
